Retina is a Marker for Cerebrovascular Heath
Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression
Mayo Clinic
100 participants
Feb 9, 2021
INTERVENTIONAL
Conditions
Summary
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
Eligibility
Inclusion Criteria2
- Age ≥18 yo.
- Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD)
Exclusion Criteria5
- Age\<18yo
- Pregnant
- Breast feeding
- Unable to follow commands
- Unable to tolerate MRI
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Cilostazol 100mg BID
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04753970